Engflag

Actan

Quick links to important sections

Actan

Actan_EN

Method of action: Antidepressant, Psychoanaleptics, Timoleptic

Treatment option: Bulimia, Bulimia Nervosa, Depression, Neurosis, Obsessive Compulsive Personality Disorder

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actan

Quick Facts

Property Description
Active Ingredient Fluoxetine (as hydrochloride salt)
Form Capsule, Tablet, Oral Solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Modulating mood and emotional balance
Origin Synthetic Compound

What is Actan? (Fluoxetine)

Actan is a prescription-only medicine whose active component is the synthetic compound Fluoxetine. It is classified as a Selective Serotonin Reuptake Inhibitor (SSRI), establishing its identity as a psychotropic agent used to modulate specific chemical activity in the brain.

Defining the Active Ingredient and Pharmaceutical Class

Actan is a pharmaceutical preparation containing the active ingredient Fluoxetine, typically administered as the hydrochloride salt. This substance is formally classified as a Selective Serotonin Reuptake Inhibitor (SSRI), distinguishing it within the broader antidepressant drug class due to its targeted mechanism. This medicine is designed to operate on specific chemical pathways in the brain. Fluoxetine is one of the most widely studied and clinically recognized compounds in the SSRI class, supported by extensive pharmacological studies.

Composition and Available Forms

Actan is a single-ingredient product designed for the oral route of administration. The product is manufactured in several standardized dosage forms, including a rigid capsule, a solid tablet, and an oral solution. These forms utilize appropriate pharmaceutical excipients—inactive ingredients—to ensure the consistent and controlled delivery of the Fluoxetine component into the gastrointestinal system for absorption.

General Therapeutic Purpose of an SSRI

The drug's general therapeutic purpose is fundamentally derived from its core mechanism: the selective inhibition of serotonin reuptake. This action prevents the rapid reabsorption of the neurotransmitter serotonin by nerve cells, which increases the amount of serotonin available in the brain. By modulating serotonergic neurotransmission, Actan is employed to support emotional balance, providing general relief from conditions marked by mood instability.

Regulatory References

  1. MedlinePlus Fluoxetine Information
  2. NIH Serotonin Reuptake Mechanism

What side effects are possible with Actan?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Actan (Fluoxetine) based on their frequency and the physiological system affected. The most frequently documented effects, classified as Very Common in regulatory summaries, include headache, insomnia, nausea, diarrhea, and fatigue. Reactions listed as Common span several body systems, including nervousness, anxiety, decreased libido, dizziness, dry mouth, rash, and weight decrease.

Adverse effects are formally categorized into System-Organ Classes (SOCs), such as Psychiatric Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Safety Alerts

Specific risks are highlighted due to their clinical significance. These serious adverse reactions documented in official labeling include the potential for Serotonin Syndrome, severe cutaneous reactions (like Stevens-Johnson syndrome), abnormal bleeding events, and Hyponatremia (low sodium levels). Antidepressant use is also associated with an increased risk of suicidal thoughts and behavior, particularly at the start of treatment or following dose changes.

Population-Specific Notes and Restrictions

Safety notes address specific patient groups. For the pediatric population, there is an increased risk of suicidal ideation. Older adults may have a greater risk of hyponatremia and bleeding. Furthermore, the medicine is restricted from use concurrently with Monoamine Oxidase Inhibitors (MAOIs), necessitating mandatory washout periods before and after treatment. The risk of adverse effects is officially noted to be highest at the start of treatment and following dose changes.

Overdose and Emergency Response

Overdose and when to seek help

Feature Official Regulatory Statement
Documented overdose presentations Overdose manifestations documented in regulatory sources range from common CNS effects like drowsiness, tremor, nausea, and vomiting to severe outcomes. These include seizures, altered mental status, and potentially fatal cardiac events such as QT prolongation and ventricular arrhythmia (Torsades de Pointes). Specific toxicity syndromes, notably Serotonin Syndrome and NMS-Like Reactions, are also associated with overdose.
Physiological systems affected (as stated in label) Central Nervous System, Cardiovascular System, Autonomic Nervous System, and Neuromuscular System.
Dose-related or exposure-related factors (if applicable) The risk of overdose severity is increased by co-ingestion with other serotonergic agents. Due to the drug’s long elimination half-life, a risk of prolonged toxicity must be considered in management.
Population-specific overdose notes (if applicable) Patients with hepatic impairment require prolonged medical observation in overdose due to delayed elimination. Increased incidence of Hyponatremia has been reported in the elderly following overdose.
Emergency-response statements (as written in official documents) Management focuses on monitoring and support of vital functions. Procedural instructions include gastric lavage and administration of activated charcoal if ingestion is recent. Treatment must be symptomatic and supportive, as no specific antidote is known.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for suspected overdose. Emergency services must be contacted immediately if the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened (coma).

Overdose Classifications

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Overdose may be associated with life-threatening outcomes, specifically Serotonin Syndrome and serious cardiac events.
Regulatory basis (EMA / FDA / etc.) Prescribing Information (US FDA) and Summary of Product Characteristics (EU EMA).
Overdose-context constraints (as defined in official documents) Continuous cardiac monitoring (ECG) is required during management due to the risk of QTc prolongation and potential arrhythmia.

Official Overdose Statements

  • Overdose presentations include common CNS effects like drowsiness and tremor, escalating to severe manifestations such as seizures and coma.
  • Documented severe risks are Serotonin Syndrome and potentially life-threatening cardiac events, including Torsades de Pointes.
  • Seek immediate medical attention for any suspected overdose; emergency services are required if the patient is unconscious or seizing.
  • Management is strictly supportive and includes monitoring of vital functions and continuous ECG monitoring, as no specific antidote is known.

The regulatory documents define the overdose profile by cataloging specific manifestations and establishing criteria for emergency intervention due to the risk of severe systemic and cardiac toxicity. Management is defined by the absence of a specific antidote and relies entirely on intensive supportive care and rigorous observation, which is prolonged for patients with underlying hepatic impairment.

Therapeutic Uses of Actan

What Actan Treats: Main Uses and Benefits

Actan is considered relevant in contexts involving certain distressing symptoms across therapeutic domains like mood and anxiety. This medication is applied when conditions present with disruptive symptom manifestations that interfere with daily functioning and comfort, helping to ease the overall symptom burden. It is considered relevant in conditions characterized by periods of heightened symptoms, including Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD).

Therapeutic Support and Symptom Relief

Actan generally provides symptomatic support for conditions involving heightened physiological activity and emotional strain. It is applied in addressing symptoms related to persistent low mood, hopelessness, and loss of pleasure in depression, providing supportive relief that helps patients cope more steadily with emotional fluctuations and supports general well-being. It may assist with managing symptoms that create noticeable functional strain, such as lessening the frequency of overwhelming panic attacks or regulating the severe, cyclical mood swings and irritability of PMDD. The medication is commonly used across conditions presenting with acute episodes and contributes to improved comfort during symptomatic periods. The medication may be part of symptomatic management applied in situations requiring short-term symptomatic support, relevant in contexts involving heightened systemic burden, such as Treatment Resistant Depression and Depressive Episodes Associated with Bipolar I Disorder.

“It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional comfort during symptomatic periods.”

Quick Fact: Relief for Affective and Behavioral Symptoms

Property Description
Primary Symptom Domains Persistent low mood, panic attacks, obsessive thoughts, behavioral dyscontrol.
Clinical Scenarios Acute stabilization, long-term maintenance, cyclical/intermittent use (for PMDD), combination regimens.
Patient Benefit Supports general well-being, contributes to improved comfort, assists with maintaining functional comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Actan? (Fluoxetine)

The population eligibility for Actan is determined by official regulatory classifications, defining groups for whom the medicine is strictly prohibited, restricted, or established for use.

Eligibility Status Applicable Population/Condition
Absolutely Contraindicated Patients with known hypersensitivity to Fluoxetine. Concomitant use with MAOIs intended to treat psychiatric disorders, or with Pimozide or Thioridazine.
Use Established Adult patients for all approved indications. Pediatric patients aged 8 and older (MDD) or 7 and older (OCD) for specific indications.
Conditional/Restricted Use Patients with Hepatic Impairment (e.g., cirrhosis) require a lower or less frequent dose consideration. Use requires caution in the elderly and in patients with a history of seizures or QT prolongation risk factors.
Not Recommended Lactating/Nursing Mothers; Fluoxetine and its active metabolite are excreted into breast milk. Pregnancy use is justified only if the potential benefit outweighs the potential risks to the fetus.

Eligibility is primarily restricted by absolute drug-to-drug prohibitions and age minimums. Use is not established in children younger than the minimum approved age for each indication. These official statements define the boundaries of who can and cannot use the medicine according to regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Actan (Fluoxetine) defines interaction patterns primarily through formal prohibitions and pharmacokinetic effects.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), Pimozide, and Thioridazine is prohibited. This restriction addresses the high risk of serious outcomes like Serotonin Syndrome and QTc prolongation. Due to the long half-life of Actan, mandatory timing separation rules are required: an MAOI must not be started within 5 weeks of discontinuing Actan, and Actan must not be started within 14 days of discontinuing an MAOI.

Pharmacokinetic and Pharmacodynamic Effects

Actan is a potent inhibitor of the CYP2D6 isoenzyme. This results in the elevation of plasma concentrations for co-administered drugs metabolized by this pathway, including Tricyclic Antidepressants (TCAs) and certain Antiarrhythmics. Co-administration with other serotonergic agents (e.g., Triptans, St. John's Wort) or drugs that interfere with hemostasis (e.g., NSAIDs, Warfarin) may result in an additive risk of Serotonin Syndrome and bleeding, respectively. Use with alcohol is advised against due to potential additive effects on impairment of alertness. Conditions like hepatic impairment can increase systemic exposure, thereby heightening the risk of certain interactions.

Mechanism of Action

Central Cholinergic Blockade and Motor Control

Actan functions as a non-selective antagonist of muscarinic acetylcholine receptors (mAChRs), with a central focus on the M1 and M4 subtypes within the basal ganglia. This mechanism blocks excessive excitatory signaling mediated by the neurotransmitter acetylcholine, thereby modulating the ratio of dopaminergic to cholinergic activity in the striatum. This action alters signaling output within motor circuits and subsequent alteration of muscle tone and kinetic activity.

Modulation of Peripheral Autonomic Functions

The drug also acts by blocking muscarinic receptors on peripheral glandular and smooth muscle tissues. This peripheral antagonism alters the function of exocrine glands and smooth muscle tissues, resulting in reduced secretory output (e.g., decreased saliva and sweat production) and decreased basal muscle tone (e.g., in the bladder and gastrointestinal tract).

Dosage and Administration Information

How to Use Actan

Actan (Fluoxetine) is administered exclusively through the oral route, available as an immediate-release capsule/tablet, an oral solution, and a delayed-release 90 mg capsule for once-weekly administration. The specific dosage and frequency are determined by the indication and follow standard guidelines.

Dosing and Frequency Principles

Actan is typically taken once daily, often in the morning, and may be administered with or without food. The standard starting dose for conditions such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) is 20 mg per day, with maintenance ranges extending up to 60 mg per day. The maximum daily dose for these conditions is 80 mg. For Bulimia Nervosa, the recommended dose is a fixed 60 mg per day.

Indication Starting Dose Maximum Dose
MDD / OCD 20 mg per day 80 mg per day
Bulimia Nervosa 60 mg per day 60 mg per day

Administration Context and Adjustments

Dosing can be titrated over several weeks. A weekly regimen is possible using the 90 mg delayed-release capsule for MDD maintenance. Administration for Premenstrual Dysphoric Disorder (PMDD) may follow a continuous daily schedule or an intermittent schedule starting before menstruation. Specific instructions for the oral solution require it to be shaken well before measuring. Furthermore, lower or less frequent dosing is specified for populations such as older adults and individuals with hepatic impairment.

Recent Clinical Evidence

Research Evidence for Major Depressive Disorder (MDD)

Actan was studied for conditions associated with acute or disruptive episodes of Major Depressive Disorder (MDD). The primary research involves many Randomized Controlled Trials (RCTs) against an inactive substance (placebo) to explore short-term symptom changes over about 8 to 12 weeks. Findings were mixed across studies when comparing Actan directly against certain older antidepressant medications. In the longer-term maintenance research, data show patterns related to a rate of symptom recurrence that was lower in participants who continued treatment compared to those who discontinued it. However, the certainty remains low regarding outcomes after a specific period, as follow-up durations were limited in many studies.

Research Evidence for Obsessive-Compulsive Disorder (OCD) and Bulimia Nervosa (BN)

Research examined Actan’s application in conditions involving periods of heightened symptoms of OCD. Placebo-controlled RCTs were designed to observe changes in the frequency and severity of obsessive thoughts and compulsive behaviors. Findings indicate that the onset of measured symptom change may be slower and was observed in some studies to require longer observation periods.

For Bulimia Nervosa (BN), key evidence relies on placebo-controlled RCTs focusing on the quantification of core bulimic behaviors. Studies monitored the change in the frequency of binge eating episodes and purging episodes. Research highlights changes measured during the study period, reporting patterns of a reduced frequency of these behaviors.

Evidence in Specific Populations and Uncertainties

Dedicated placebo-controlled RCTs were conducted for children and adolescents with MDD and OCD. Scientific reviews noted that the measured effect size was reported to be of modest magnitude compared to adult trials. Older adults with MDD were also observed in specific studies, but the follow-up durations were limited. Overall, the results apply only to the populations studied, and data for certain groups remain insufficient. Scientific reviews indicate that while a substantial research base exists, certain areas remain topics of ongoing research. Evidence quality varies across studies, and there is limited information for long-term outcomes concerning the maintenance of effect beyond the initial follow-up periods.

Key Studies & References

  1. Fluoxetine: MedlinePlus Drug Information
  2. Depression in adults: recognition and management (NICE Guideline NG222)

How should Actan be stored and disposed of?

Storage and Disposal Requirements for Actan (Fluoxetine)

The official regulatory documents specify mandatory conditions for the storage and disposal of Actan.

Requirement Storage Condition
Temperature Store at Controlled Room Temperature, typically 20 °C to 25 °C (68 °F to 77 °F). Do not store above 25 °C.
Protection Keep the container closed tightly and protect from light and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal must align with official guidelines. The product should be disposed of primarily through an authorized drug take-back program. Actan is not recommended for disposal by flushing down the toilet. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

flagEcuador

Equivalent of Actan found in:

A-Z Index: